EMA401

EMA401
Clinical data
Routes of; administration	Oral
Legal status
Legal status	Phase II Clinical Trials;
Pharmacokinetic data
Bioavailability	33%
Protein binding	Angiotensin II Subtype 2 Receptor
Elimination half-life	6-12 hr
Identifiers
	IUPAC name (S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylic acid;
CAS Number	1316755-17-5;
PubChem CID	9937291;
ChemSpider	8068121;
UNII	P9EW7EP34P;
ChEBI	CHEBI:150942;
ChEMBL	ChEMBL34124;
CompTox Dashboard (EPA)	DTXSID101031601 ;
Chemical and physical data
Formula	C32H29NO5
Molar mass	507.586 g·mol−1
3D model (JSmol)	Interactive image;
Specific rotation	+
Density	1.256±0.06 g/cm3
Boiling point	745.3 ± 60.0 °C (1,373.5 ± 108.0 °F)
Solubility in water	14 mg/mL (20 °C)
	SMILES COC1=C(C2=C(CN(C(C2)C(=O)O)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4)C=C1)OCC5=CC=CC=C5;
	InChI InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36); Key:GHBCIXGRCZIPNQ-UHFFFAOYSA-N;

EMA401 is a drug under development for the treatment of peripheral neuropathic pain. Trials were discontinued in 2015, with new trials scheduled to begin March, 2018. It was initially established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pain EMA401 has shown efficacy in preclinical models of shingles, diabetes, osteoarthritis, HIV and chemotherapy. EMA401 is a competitive antagonist of angiotensin II type 2 receptor (AT₂R) being developed by the Australian biotechnology company Spinifex Pharmaceuticals. EMA401 target angiotensin II type 2 receptors, which may have importance for painful sensitisation.